본문으로 건너뛰기
← 뒤로

[Precision medicine in endocrinology exemplified by medullary thyroid cancer].

1/5 보강
Innere Medizin (Heidelberg, Germany) 2024 Vol.65(3) p. 202-210
Retraction 확인
출처

Brandenburg T, Machlah YM, Führer D

📝 환자 설명용 한 줄

Medullary thyroid cancer (MTC) is a prime example for precision medicine in endocrinology and underlines the immediate benefits of basic, translational and healthcare research for patients with a rare

이 논문을 인용하기

↓ .bib ↓ .ris
APA Brandenburg T, Machlah YM, Führer D (2024). [Precision medicine in endocrinology exemplified by medullary thyroid cancer].. Innere Medizin (Heidelberg, Germany), 65(3), 202-210. https://doi.org/10.1007/s00108-023-01635-6
MLA Brandenburg T, et al.. "[Precision medicine in endocrinology exemplified by medullary thyroid cancer].." Innere Medizin (Heidelberg, Germany), vol. 65, no. 3, 2024, pp. 202-210.
PMID 38231404 ↗

Abstract

Medullary thyroid cancer (MTC) is a prime example for precision medicine in endocrinology and underlines the immediate benefits of basic, translational and healthcare research for patients with a rare disease in clinical . A mutation in the rearranged during transfection (RET) proto-oncogene that codes for a transmembrane receptor protein tyrosine kinase, leads to constitutive activation of the kinase, which is the decisive pathomechanism for the disease. The MTC occurs in a sporadic (somatic RET mutation) or hereditary form (RET germline mutation, multiple endocrine neoplasia types 2 and 3). For germline mutation carriers the timing of preventive thyroidectomy depends on the RET genotype. For advanced metastasized RET-mutant MTC, selective RET kinase inhibitors are available, which are currently considered to be game changers in the treatment. Based on the specific tumor marker calcitonin, MTC can be identified at an early stage during the differential diagnosis of thyroid nodules. The preoperative calcitonin level even enables statements on the degree of dissemination of the disease and on the probability of a cure through surgery. A new development is the consideration of desmoplasia as a histopathological biomarker for the metastatic potential of a MTC, which could possibly modify the operative approach as well as the future MTC nomenclature. Furthermore, the postoperative calcitonin level and the calcitonin doubling time are highly valid prognostic markers for tumor burden and biological aggressiveness of MTC and therefore decisive for patient follow-up. Biochemical, molecular and histological markers enable a risk-adapted surgical treatment and together with new targeted systemic treatments have contributed to a paradigm shift in the diagnostics, prognosis and treatment of MTC in recent years. Endocrine precision medicine for MTC therefore enabled a change from the previous purely symptom-oriented to a modern preventive and individualized treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (3)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반